GnRH Agonists for Prostate Cancer: How They Work

Peptides in Oncology

95% castration rate

GnRH agonists achieve castrate testosterone levels (below 50 ng/dL) in approximately 95% of prostate cancer patients within 2-4 weeks, making them the standard of care for androgen deprivation therapy.

Casati et al., Biochemical Pharmacology, 2023

Casati et al., Biochemical Pharmacology, 2023

View as image

Prostate cancer cells need testosterone to grow. Remove testosterone, and most prostate tumors shrink. This principle, established by Charles Huggins in 1941 (for which he received the Nobel Prize), drives the most common systemic treatment for advanced prostate cancer: androgen deprivation therapy (ADT). GnRH agonists are peptide drugs that achieve medical castration by exploiting a paradox in endocrine physiology. The hypothalamus normally releases gonadotropin-releasing hormone (GnRH) in pulses to stimulate testosterone production. Continuous, non-pulsatile GnRH exposure does the opposite: it overwhelms and downregulates pituitary GnRH receptors, shutting down the entire hypothalamic-pituitary-gonadal axis.^[1] Four GnRH agonist peptides are approved for prostate cancer: leuprolide (Lupron), goserelin (Zoladex), triptorelin (Trelstar), and histrelin (Vantas). Together, they have been the backbone of ADT for over four decades. For the broader biology of this hormone, see GnRH: the master switch for reproductive hormones. For GnRH agonists in other contexts, see GnRH agonists for breast cancer and GnRH agonists for endometriosis.

The paradox: how agonists become suppressors

GnRH is a 10-amino acid peptide (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) released from the hypothalamus in pulses every 60-120 minutes.^[1] This pulsatile pattern is essential. Each pulse triggers the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH then stimulates testicular Leydig cells to produce testosterone.

When a GnRH agonist is administered as a continuous depot injection, it initially mimics GnRH and stimulates the pituitary. LH and testosterone surge during the first 1-2 weeks. But continuous receptor stimulation triggers a cascade of molecular events: GnRH receptors are internalized, degraded, and no longer replenished on the cell surface. The pituitary gonadotroph cells become desensitized. Within 2-4 weeks, LH and FSH secretion collapses, and testosterone falls to castrate levels (below 50 ng/dL, and often below 20 ng/dL).

This desensitization is reversible. When the GnRH agonist is discontinued, pituitary receptors gradually recover, LH secretion resumes, and testosterone production restarts over weeks to months. The reversibility distinguishes medical castration from surgical orchiectomy (bilateral removal of the testes), which produces permanent castration.

The testosterone flare problem

The initial testosterone surge during GnRH agonist initiation is not a theoretical concern. In patients with metastatic prostate cancer, the flare can cause bone pain exacerbation, urinary obstruction from tumor swelling, and in rare cases spinal cord compression from vertebral metastases. Tumor flare symptoms have been reported in up to 63% of patients with advanced disease.

To prevent flare, an antiandrogen (bicalutamide 50 mg daily or flutamide 250 mg three times daily) is started 1-2 weeks before the GnRH agonist and continued for 2-4 weeks after initiation. The antiandrogen blocks testosterone from binding to the androgen receptor on cancer cells, neutralizing the effects of the temporary testosterone surge without interfering with the GnRH agonist's mechanism.

GnRH antagonists (degarelix, relugolix) were developed specifically to avoid this flare. They competitively block the GnRH receptor immediately, suppressing LH and testosterone within 1-3 days without any initial surge. Patel et al. (2024) reviewed the comparative pharmacology of GnRH peptide antagonists and their formulation challenges.^[2]

The four approved GnRH agonist peptides

Leuprolide (Lupron)

Leuprolide was the first GnRH agonist approved for prostate cancer (1985). It is a nonapeptide with D-leucine substitution at position 6 and ethylamide at the C-terminus, making it resistant to enzymatic degradation. Available as monthly, 3-month, 4-month, and 6-month depot injections (subcutaneous or intramuscular). The 6-month formulation (Eligard 45 mg) provides the longest interval between injections in the class. Leuprolide is the most prescribed GnRH agonist worldwide.

Goserelin (Zoladex)

Goserelin is delivered as a biodegradable implant injected subcutaneously into the anterior abdominal wall. Available in 1-month (3.6 mg) and 3-month (10.8 mg) formulations. The implant dissolves over the dosing period, providing sustained release. Some comparative data suggests goserelin may maintain testosterone suppression below 50 ng/dL more consistently than leuprolide, though head-to-head trials are limited.

Triptorelin (Trelstar)

Triptorelin is notable for achieving the most profound testosterone suppression among the GnRH agonists. In a three-way comparison, triptorelin produced the lowest mean testosterone levels and the highest rate of chemical castration below 10 ng/dL. Available as 1-month (3.75 mg), 3-month (11.25 mg), and 6-month (22.5 mg) intramuscular injections. The clinical significance of achieving testosterone below 10 ng/dL versus below 50 ng/dL remains debated, with emerging evidence suggesting deeper suppression may improve outcomes in high-risk disease.

Histrelin (Vantas)

Histrelin is unique: it is delivered as a subcutaneous implant placed in the inner arm that provides continuous GnRH agonist release for 12 months. The implant is removed and replaced annually. This eliminates the need for monthly or quarterly injections but requires a minor surgical procedure for insertion and removal. Testosterone suppression is sustained and consistent throughout the 12-month period.

How GnRH agonists compare to antagonists

GnRH antagonists represent a mechanistically different approach to testosterone suppression. Rather than desensitizing the receptor through overstimulation, they competitively block GnRH from binding its receptor, producing immediate LH and testosterone suppression.

Degarelix (Firmagon) is a peptide GnRH antagonist given as monthly subcutaneous injections. It achieves castrate testosterone within 3 days (versus 2-4 weeks for agonists) with no flare. The HERO trial demonstrated that the oral non-peptide antagonist relugolix (Orgovyx) achieved sustained testosterone suppression of 96.7% at 48 weeks, compared to 88.8% for leuprolide.

Paoletti et al. (2025) reviewed the pharmacokinetic considerations for both agonists and antagonists, noting that non-peptide oral antagonists like relugolix combine rapid onset, no flare, and the convenience of oral dosing.^[3] Despite these advantages, GnRH agonists remain more widely used for several reasons: decades of clinical experience, availability of long-acting depot formulations (up to 12 months), lower cost, and physician familiarity. The antagonist market share is growing but has not displaced agonists as the default choice.

Side effects of androgen deprivation

The side effects of GnRH agonists are primarily those of testosterone deficiency, not of the peptide itself. Both agonists and antagonists produce the same ADT-related adverse effects:

Hot flashes affect 50-80% of patients and are the most commonly reported symptom. They result from hypothalamic thermoregulatory dysfunction in the absence of sex steroids.

Bone density loss is progressive during ADT, with studies showing 2-8% bone mineral density loss per year. Bisphosphonates or denosumab are often co-prescribed for patients on long-term ADT.

Metabolic changes include increased body fat, decreased lean muscle mass, insulin resistance, and lipid abnormalities. The metabolic syndrome incidence increases with ADT duration.

Cardiovascular risk has been a major area of debate. Some observational studies suggested GnRH agonists carry higher cardiovascular risk than antagonists, possibly related to the testosterone flare or to direct GnRH receptor effects on the vasculature. The PRONOUNCE trial was designed to test this hypothesis but was terminated early due to poor enrollment and the COVID-19 pandemic, leaving the question incompletely answered.

Cognitive and mood effects include fatigue, depression, and potential cognitive decline. These effects are difficult to disentangle from the psychological impact of a cancer diagnosis and treatment.

Next-generation GnRH peptide design

Moradi et al. (2015) demonstrated that glycosylation of LHRH analogs dramatically improved their enzymatic stability and anticancer activity.^[4] Glycosylated compounds showed half-lives extended from 3 minutes to up to 103 minutes in kidney membrane enzyme assays. These glycopeptides also exhibited significant antiproliferative effects against LHRH receptor-positive prostate cancer cell lines (LNCaP and DU145), suggesting a dual mechanism: both hormonal suppression and direct cytotoxic effects on cancer cells expressing GnRH receptors.

This direct anticancer effect exploits the fact that many prostate cancer cells express GnRH receptors on their surface. Native GnRH and its analogs can directly inhibit proliferation of these cells through autocrine/paracrine signaling pathways independent of the pituitary axis. Several peptide-drug conjugates have been designed to target these receptors for directed delivery of cytotoxic payloads, though none have reached late-stage clinical development for prostate cancer.

Chi et al. (2025) reported on SHR7280, an oral GnRH antagonist peptide being developed by Jiangsu Hengrui, demonstrating the ongoing innovation in this drug class.^[5] The shift from injectable peptide agonists to oral non-peptide antagonists reflects the broader trend in peptide pharmacology toward improved convenience and reduced injection burden.

Intermittent versus continuous therapy

Whether ADT must be continuous or can be given intermittently has been studied in multiple trials. Intermittent ADT uses cycles of treatment (typically 6-9 months) followed by off-treatment periods until PSA rises above a threshold. During off-treatment periods, testosterone recovers and quality-of-life metrics improve.

The SWOG 9346 trial compared continuous to intermittent ADT in metastatic hormone-sensitive prostate cancer. Intermittent therapy was non-inferior for overall survival in extensive disease, though the confidence intervals were wide. The approach is more commonly applied in the biochemical recurrence setting (rising PSA after local therapy) where the disease burden is low and the side effect burden of continuous ADT is harder to justify.

The hypothalamic-pituitary-gonadal axis biology is relevant here: the PACAP-mediated regulation of GnRH neurons described by Faludi et al. (2025) demonstrates that multiple neuropeptide systems modulate GnRH release, with PACAP knockout reducing GnRH neuron numbers and altering kisspeptin signaling.^[6] This complexity explains why axis recovery after GnRH agonist withdrawal is variable and sometimes incomplete, particularly in older patients or after prolonged therapy.

Where the evidence stands

GnRH agonists remain the most prescribed form of ADT for prostate cancer, with over four decades of clinical data supporting their efficacy in castration-sensitive disease. The testosterone flare is their primary mechanistic disadvantage compared to antagonists. The side effects are those of testosterone deprivation itself, shared equally by all forms of ADT including surgical castration.

The future of GnRH-based prostate cancer treatment is trending toward antagonists (oral relugolix, injectable degarelix) for their faster onset and flare-free profile, and toward combination strategies pairing ADT with newer agents (abiraterone, enzalutamide, darolutamide, docetaxel) in earlier disease stages. The peptide pharmacology of GnRH analogs continues to evolve, with glycosylated derivatives and targeted conjugates representing potential next-generation approaches.

The Bottom Line

GnRH agonists achieve medical castration in prostate cancer by continuously stimulating pituitary GnRH receptors until they downregulate, suppressing testosterone to castrate levels within 2-4 weeks. Four peptide agonists (leuprolide, goserelin, triptorelin, histrelin) are approved, differing primarily in formulation and injection interval. The testosterone flare during the first 1-2 weeks requires antiandrogen cover and remains their key disadvantage versus GnRH antagonists, which suppress testosterone within days without flare. Side effects are those of testosterone deprivation itself. The field is shifting toward oral antagonists for convenience, while peptide engineering efforts focus on glycosylated analogs with enhanced stability and direct anticancer activity.

Frequently Asked Questions

How do GnRH agonists work for prostate cancer?

GnRH agonists work by continuously stimulating the pituitary gland's GnRH receptors, which paradoxically shuts them down. Normal GnRH is released in pulses to trigger testosterone production. Continuous exposure causes the pituitary to internalize and degrade its GnRH receptors, stopping LH secretion and reducing testosterone to castrate levels (below 50 ng/dL) within 2-4 weeks.

What is the testosterone flare with GnRH agonists?

The testosterone flare is a temporary testosterone surge during the first 1-2 weeks of GnRH agonist therapy, before pituitary receptor downregulation occurs. In patients with metastatic prostate cancer, this flare can worsen bone pain, cause urinary obstruction, or in rare cases trigger spinal cord compression. An antiandrogen (bicalutamide or flutamide) is given before and during initiation to block the flare's effects.

Which GnRH agonist is best for prostate cancer?

All four approved GnRH agonists (leuprolide, goserelin, triptorelin, histrelin) effectively suppress testosterone to castrate levels in approximately 95% of patients. Head-to-head comparisons suggest triptorelin may achieve the deepest testosterone suppression (below 10 ng/dL). Leuprolide is most widely prescribed due to formulation variety (1-6 month depots). Histrelin offers a 12-month implant for patients wanting fewer interventions.

Are GnRH antagonists better than agonists for prostate cancer?

GnRH antagonists (degarelix, relugolix) achieve castrate testosterone in 1-3 days versus 2-4 weeks for agonists, without the initial testosterone flare. The HERO trial showed oral relugolix achieved sustained castration in 96.7% of patients versus 88.8% for leuprolide at 48 weeks. However, agonists offer long-acting depot formulations (up to 12 months) and decades of clinical experience.

How long do GnRH agonists take to lower testosterone?

GnRH agonists typically reduce testosterone to castrate levels (below 50 ng/dL) within 2-4 weeks of the first injection. During the first 1-2 weeks, testosterone paradoxically increases before pituitary receptor downregulation takes effect. GnRH antagonists like degarelix achieve castration faster, within 1-3 days, without any initial testosterone surge.

What are the long-term side effects of GnRH agonists?

Long-term GnRH agonist use causes effects of testosterone deprivation: hot flashes (50-80% of patients), progressive bone density loss (2-8% per year), increased body fat and decreased muscle mass, insulin resistance, lipid abnormalities, fatigue, and potential cognitive changes. These side effects are shared by all forms of androgen deprivation therapy, including surgical castration and GnRH antagonists.